Journal
CHEST
Volume 133, Issue 6, Pages 199S-233SPublisher
ELSEVIER
DOI: 10.1378/chest.08-0672
Keywords
abciximab; antiplatelet drugs; aspirin; clopidogrel; dipyridamole; eptifibatide; platelet pharmacology; resistance; ticlopidine; tirofiban
Categories
Funding
- Medical Research Council [MC_U137686849] Funding Source: Medline
- Medical Research Council [MC_U137686849] Funding Source: researchfish
- MRC [MC_U137686849] Funding Source: UKRI
Ask authors/readers for more resources
This article about currently available antiplatelet drugs is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). it describes the mechanism of action, pharmacokinetics, and pharmacodynamics of aspirin, reversible cyclooxygenase inhibitors, thienopyridines, and integrin alpha IIb beta 3 receptor antagonists. The relationships among dose, efficacy, and safety are thoroughly discussed, with a mechanistic overview of randomized clinical trials. The article does not provide specific management recommendations; however, it does highlight important practical aspects related to antiplatelet therapy, including the optimal dose of aspirin, the variable balance of benefits and hazards in different clinical settings, and the issue of interindividual variability in response to antiplatelet drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available